INT167964

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.58
First Reported 2006
Last Reported 2010
Negated 3
Speculated 0
Reported most in Body
Documents 30
Total Number 30
Disease Relevance 25.41
Pain Relevance 10.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (Aes)
Anatomy Link Frequency
fibroblast 1
bowel 1
Aes (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Ziconotide 960 99.80 Very High Very High Very High
headache 33 99.00 Very High Very High Very High
Central nervous system 17 98.92 Very High Very High Very High
pregabalin 85 98.88 Very High Very High Very High
depression 48 98.56 Very High Very High Very High
Pain 469 96.72 Very High Very High Very High
Oxycodone 267 96.68 Very High Very High Very High
nud 15 96.60 Very High Very High Very High
narcan 214 95.88 Very High Very High Very High
Pain score 62 95.28 Very High Very High Very High
Disease Link Frequency Relevance Heat
Vomiting 123 100.00 Very High Very High Very High
Cognitive Disorder 86 100.00 Very High Very High Very High
Confusion 72 100.00 Very High Very High Very High
Congenital Anomalies 29 100.00 Very High Very High Very High
Heart Rate Under Development 11 100.00 Very High Very High Very High
Neutropenia 99 99.64 Very High Very High Very High
Alopecia 18 99.64 Very High Very High Very High
Weight Loss 24 99.52 Very High Very High Very High
Infection 33 99.46 Very High Very High Very High
Contracture 1 99.32 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In doing so, we found several classes of AEs and preventable AEs.
Neg (preventable) Gene_expression (preventable) of AEs
1) Confidence 0.58 Published 2008 Journal BMC Health Serv Res Section Body Doc Link PMC2621200 Disease Relevance 0.08 Pain Relevance 0
The most common AEs that occurred in ?
Gene_expression (occurred) of AEs
2) Confidence 0.31 Published 2010 Journal BMC Fam Pract Section Body Doc Link PMC2988717 Disease Relevance 1.57 Pain Relevance 1.55
Seven patients were not evaluable for response as they do not receive at least three cycles: three died (two because of unknown reasons and one because of an infection), two patients because of AEs and two because of a decrease in ECOG performance status.
Gene_expression (two) of AEs associated with infection
3) Confidence 0.31 Published 2010 Journal Br J Cancer Section Body Doc Link PMC2883700 Disease Relevance 0.46 Pain Relevance 0
The neurocognitive AEs, such as confusion, disorientation, memory impairment, speech difficulties, impaired concentration, mental slowing, or thought abnormalities, are the most troublesome of the ziconotide-related CNS AEs and, if not manageable by dose reduction, often required drug discontinuation.38
Gene_expression (troublesome) of AEs associated with cognitive disorder, congenital anomalies, ziconotide, central nervous system and confusion
4) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 2.19 Pain Relevance 0.81
One patient (patient 1) reported AEs (nausea and vomiting with dehydration) during treatment with ziconotide, but the AEs were considered unrelated to ziconotide therapy.49
Gene_expression (considered) of AEs associated with ziconotide, volume depletion and dehydration and vomiting
5) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 0.79 Pain Relevance 1.59
g/hour, respectively, due to AEs.38
Gene_expression (respectively) of AEs
6) Confidence 0.30 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 1.98 Pain Relevance 1.32
The most frequently reported AEs were reduction in appetite (28.0%), weight loss (10.0%), and increased phenytoin levels in patients concurrently taking phenytoin (10.0%).
Gene_expression (reduction) of AEs associated with weight loss
7) Confidence 0.30 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 1.10 Pain Relevance 0.04
Resolution of most AEs was reported to occur with adjustments of dosage or drug regimen.
Gene_expression (Resolution) of AEs
8) Confidence 0.30 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 0.68 Pain Relevance 0
Three patients (20.0%) experienced AEs, including weight loss, headache, and dizziness, which resolved with maintenance (Wallace 1998; Kothare et al 2004).
Gene_expression (experienced) of AEs associated with weight loss, dizziness and headache
9) Confidence 0.30 Published 2006 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2671817 Disease Relevance 1.33 Pain Relevance 0.14
An important limitation of this study is that it is unlikely that rare AEs would have been detected.
Gene_expression (detected) of AEs
10) Confidence 0.27 Published 2009 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2710384 Disease Relevance 0.51 Pain Relevance 0.93
At the same time, the 12-week study period was long enough to demonstrate the LDL-C reducing effect and possible AEs of statin therapy (Brown et al 2002; Olsson et al 2002).
Gene_expression (reducing) of AEs
11) Confidence 0.18 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2663459 Disease Relevance 0.54 Pain Relevance 0
It was also observed that PFD reduces AEs such as capsule contracture in mammary implants in an animal model, Gancedo et al. [68] observed a reduction in capsule thickness around submmamary tissue, along with a decrease in fibroblast-like cell proliferation, and recruitment and infiltration of inflammatory cells.
Gene_expression (reduces) of AEs in fibroblast associated with inflammation and contracture
12) Confidence 0.11 Published 2010 Journal Fibrogenesis Tissue Repair Section Body Doc Link PMC2944211 Disease Relevance 1.41 Pain Relevance 0.11
Tolerability was evaluated by recording AEs during the entire study period.
Gene_expression (recording) of AEs
13) Confidence 0.10 Published 2008 Journal BMC Musculoskelet Disord Section Body Doc Link PMC2542997 Disease Relevance 1.04 Pain Relevance 0.17
Although AEs existed in this study, therapy was well tolerated.
Gene_expression (existed) of AEs
14) Confidence 0.09 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1764758 Disease Relevance 1.25 Pain Relevance 0
About one-third of AEs in each group were judged by investigators as likely related to treatment (MF/F 200/10 ?
Gene_expression (third) of AEs
15) Confidence 0.08 Published 2010 Journal The Journal of Asthma Section Body Doc Link PMC2993043 Disease Relevance 0.69 Pain Relevance 0.09
Discontinuation due to adverse events (AEs) occurred in 23.0% and 26.0% of patients receiving milnacipran 100 mg/day and 200 mg/day, respectively, compared with 12.1% of placebo-treated patients.71 Nausea and palpitations were the only AEs resulting in discontinuation in ?
Gene_expression (occurred) of AEs associated with heart rate under development and vomiting
16) Confidence 0.07 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877602 Disease Relevance 0.65 Pain Relevance 0.24
Discontinuation due to adverse events (AEs) occurred in 23.0% and 26.0% of patients receiving milnacipran 100 mg/day and 200 mg/day, respectively, compared with 12.1% of placebo-treated patients.71 Nausea and palpitations were the only AEs resulting in discontinuation in ?
Gene_expression (occurred) of AEs associated with heart rate under development and vomiting
17) Confidence 0.07 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2877602 Disease Relevance 0.71 Pain Relevance 0.24
The most frequently reported AEs (incidence ?
Gene_expression (incidence) of AEs
18) Confidence 0.06 Published 2008 Journal Archives of Drug Information Section Body Doc Link PMC2773539 Disease Relevance 0.64 Pain Relevance 0.31
In the Mintzer et al (2007) study, AEs occurring at ?
Gene_expression (occurring) of AEs
19) Confidence 0.06 Published 2008 Journal Clinical Interventions in Aging Section Body Doc Link PMC2682381 Disease Relevance 2.22 Pain Relevance 0.09
There were no serious or unexpected AEs.
Neg (no) Gene_expression (unexpected) of AEs
20) Confidence 0.06 Published 2007 Journal BMC Clin Pharmacol Section Body Doc Link PMC2194660 Disease Relevance 0.24 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox